Cyclerion Looking To Partner Praliciguat Despite Phase II Fail In Diabetic Nephropathy
The Ironwood spinout thinks its sGC stimulator demonstrated benefit in reducing urine albumin levels in DN patients; notes data improve markedly if one outlier trial site is excluded.
You may also be interested in...
Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
Spun out from Ironwood with a $175m financing, Cyclerion added Bayer and Shire veteran Andreas Busch to its management team as Chief Innovation Officer as it awaits a trio of Phase II data readouts coming this year for its sGC stimulators.